Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Percentage of samples with MDR (a), phenotypic ESBL-producing (b), fluoroquinolone-resistant (c) and ... Figure 1. Percentage of samples with.

Published byΣέργιος Κρεστενίτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Percentage of samples with MDR (a), phenotypic ESBL-producing (b), fluoroquinolone-resistant (c) and ... Figure 1. Percentage of samples with."— Presentation transcript:

1 Figure 1. Percentage of samples with MDR (a), phenotypic ESBL-producing (b), fluoroquinolone-resistant (c) and ... Figure 1. Percentage of samples with MDR (a), phenotypic ESBL-producing (b), fluoroquinolone-resistant (c) and Amp-C-producing (d) E. coli at each timepoint for each treatment group and treatment overall (95% CI). D0, pretreatment; E, treatment end; M1, 1 month post-treatment; M3, 3 months post-treatment; LEX, cefalexin; AMC, amoxicillin/clavulanate; CVN, cefovecin; CLI, clindamycin; FQ, fluoroquinolone. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 73, Issue 12, 11 September 2018, Pages 3305–3316, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Percentage of isolates with resistance or susceptibility in each treatment group [overall treatment (a), ... Figure 2. Percentage of isolates with resistance or susceptibility in each treatment group [overall treatment (a), amoxicillin/clavulanate treatment (b), cefalexin treatment (c), cefovecin treatment (d), clindamycin treatment (e) and fluoroquinolone treatment (f)] at each timepoint (95% CI). AMP, ampicillin; AMC, amoxicillin/clavulanate; CIP, ciprofloxacin; CHL, chloramphenicol; NAL, nalidixic acid; TET, tetracycline; TMP, trimethoprim; Susc., fully susceptible; All, all treatment groups; D0, pretreatment; E, treatment end; M1, 1 month post-treatment; M3, 3 months post-treatment; LEX, cefalexin; CVN, cefovecin; CLI, clindamycin; FQ, fluoroquinolone. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 73, Issue 12, 11 September 2018, Pages 3305–3316, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 2. Percentage of isolates with resistance or susceptibility in each treatment group [overall treatment (a), ... Figure 2. Percentage of isolates with resistance or susceptibility in each treatment group [overall treatment (a), amoxicillin/clavulanate treatment (b), cefalexin treatment (c), cefovecin treatment (d), clindamycin treatment (e) and fluoroquinolone treatment (f)] at each timepoint (95% CI). AMP, ampicillin; AMC, amoxicillin/clavulanate; CIP, ciprofloxacin; CHL, chloramphenicol; NAL, nalidixic acid; TET, tetracycline; TMP, trimethoprim; Susc., fully susceptible; All, all treatment groups; D0, pretreatment; E, treatment end; M1, 1 month post-treatment; M3, 3 months post-treatment; LEX, cefalexin; CVN, cefovecin; CLI, clindamycin; FQ, fluoroquinolone. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 73, Issue 12, 11 September 2018, Pages 3305–3316, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Percentage of samples with MDR (a), phenotypic ESBL-producing (b), fluoroquinolone-resistant (c) and ... Figure 1. Percentage of samples with."

Similar presentations

Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response

Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.
Figure 1. Variation in population size of the donor strain HN-1 and E

Figure 1. Variation in population size of the donor strain HN-1 and E
Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.
Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.
Figure 1. Structure of two poxtA-carrying plasmids in E

Figure 1. Structure of two poxtA-carrying plasmids in E
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Figure 1. SpeI-PFGE dendrogram comparing P

Figure 1. SpeI-PFGE dendrogram comparing P
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Similar presentations

Ads by Google